This Week in Cardiology

John Mandrola, MD, discusses a variety of topics in cardiology, such as an update on Impella, TAVI vs SAVR trial results, studies on angina and PCI, complete revascularization, and Semaglutide research. The podcast covers a range of important advancements and findings in the field of cardiology, providing valuable insights for healthcare professionals.

Topics discussed in this podcast include the latest updates on Inclisiran, safety of sodium-channel blockers, analytic flexibility in research, the work-up of patients with heart failure, and blood pressure therapy in older patients.

Cardiologist John Mandrola, MD, discusses TAVR vs SAVR, renal denervation for hypertension, inclisiran for LDL reduction, and marketing in science. Topics include DEDICATE trial, alcohol-mediated renal denervation, and efficacy of inclisiran.

Cardiologist John Mandrola delves into defending colored boxes in guidelines, mysteries of non-culprit coronary lesions during PCI, and AF ablation complexities. He also discusses surrogate markers and their impact on clinical outcomes, providing insights into the latest developments in cardiology.

This week's podcast covers topics such as the TACT2 trial of chelation therapy, inter-atrial shunts for heart failure, triglyceride lowering, diltiazem, and Factor Xa anticoagulants. It discusses the lack of benefit of chelation therapy post-MI, the mixed results of interatrial shunts for HF, and the potential of triglyceride reduction. Additionally, it explores the correlation between bleeding risk and the co-administration of diltiazem and Factor Xa inhibitors.

Cardiologist John Mandrola, MD, covers ACC Recap including Impella CP in STEMI, REDUCE-AMI challenging beta-blockers post-MI, Prevent trial showing reduced cardiac events with preventive PCI, and EMPACT-MI on SGT2 inhibitors in post-MI care. Topics include device enthusiasm caution, industry payments influencing LVAD utilization, challenging cardiology practices with beta blockers, and plaque vulnerability identification and treatment implications.

Cardiologist John Mandrola discusses statins and diabetes, AADs in heart disease patients, tricuspid valve interventions, and an ACC preview. Topics include statin therapy's link to new onset diabetes, efficacy of statin trials, FDA approval of TriClip for tricuspid regurgitation, and upcoming ACC trials like the danger shock trial comparing Impella vs. standard care in cardiogenic shock.

Cardiologist John Mandrola, MD, discusses topics like intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, ECG importance, and industry conflicts. He covers studies on time-restricted eating, stroke prevention, and revised LBBB definition. The podcast is filled with insightful discussions for healthcare professionals.

Topics discussed include the use of obesity drugs as heart modifiers, the accuracy of wearable heart rate monitors, challenges in interpreting signals from trials, and the implications of study findings for individualized treatments in cardiology.

This podcast delves into the intriguing topics of plastics and heart disease, MINT trial LTE and Bayes theorem, and Brugada syndrome. The discussion explores the link between plastic particles in carotid plaques and CV events, the implications of test accuracy and prior probabilities in medical diagnostics, and the demographics and findings of Brugada Syndrome patients.